BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38030258)

  • 1. Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol.
    Hull MA; Ow PL; Ruddock S; Brend T; Smith AF; Marshall H; Song M; Chan AT; Garrett WS; Yilmaz O; Drew DA; Collinson F; Cockbain AJ; Jones R; Loadman PM; Hall PS; Moriarty C; Cairns DA; Toogood GJ
    BMJ Open; 2023 Nov; 13(11):e077427. PubMed ID: 38030258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid.
    Cockbain AJ; Volpato M; Race AD; Munarini A; Fazio C; Belluzzi A; Loadman PM; Toogood GJ; Hull MA
    Gut; 2014 Nov; 63(11):1760-8. PubMed ID: 24470281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial.
    Higurashi T; Hosono K; Endo H; Takahashi H; Iida H; Uchiyama T; Ezuka A; Uchiyama S; Yamada E; Ohkubo H; Sakai E; Maeda S; Morita S; Natsumeda Y; Nagase H; Nakajima A
    BMC Cancer; 2012 Sep; 12():413. PubMed ID: 22992267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The omega-3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MC-26 colorectal cancer cell liver metastasis via inhibition of PGE2-dependent cell motility.
    Hawcroft G; Volpato M; Marston G; Ingram N; Perry SL; Cockbain AJ; Race AD; Munarini A; Belluzzi A; Loadman PM; Coletta PL; Hull MA
    Br J Pharmacol; 2012 Jul; 166(5):1724-37. PubMed ID: 22300262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
    Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
    Trials; 2013 Jul; 14():237. PubMed ID: 23895505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis.
    Volpato M; Perry SL; Marston G; Ingram N; Cockbain AJ; Burghel H; Mann J; Lowes D; Wilson E; Droop A; Randerson-Moor J; Coletta PL; Hull MA
    Oncotarget; 2016 May; 7(19):28139-50. PubMed ID: 27058904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver resection surgery compared with thermal ablation in high surgical risk patients with colorectal liver metastases: the LAVA international RCT.
    Davidson B; Gurusamy K; Corrigan N; Croft J; Ruddock S; Pullan A; Brown J; Twiddy M; Birtwistle J; Morris S; Woodward N; Bandula S; Hochhauser D; Prasad R; Olde Damink S; Coolson M; Laarhoven KV; de Wilt JH
    Health Technol Assess; 2020 Apr; 24(21):1-38. PubMed ID: 32370822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases.
    Watson H; Cockbain AJ; Spencer J; Race A; Volpato M; Loadman PM; Toogood GJ; Hull MA
    Prostaglandins Leukot Essent Fatty Acids; 2016 Dec; 115():60-66. PubMed ID: 27914515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial.
    Hull MA; Sprange K; Hepburn T; Tan W; Shafayat A; Rees CJ; Clifford G; Logan RF; Loadman PM; Williams EA; Whitham D; Montgomery AA;
    Lancet; 2018 Dec; 392(10164):2583-2594. PubMed ID: 30466866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
    Schimanski CC; Möhler M; Schön M; van Cutsem E; Greil R; Bechstein WO; Hegewisch-Becker S; von Wichert G; Vöhringer M; Heike M; Heinemann V; Peeters M; Kanzler S; Kasper S; Overkamp F; Schröder J; Seehofer D; Kullmann F; Linz B; Schmidtmann I; Smith-Machnow V; Gockel I; Lang H; Galle PR
    BMC Cancer; 2012 Apr; 12():144. PubMed ID: 22494623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.
    Bridgewater JA; Pugh SA; Maishman T; Eminton Z; Mellor J; Whitehead A; Stanton L; Radford M; Corkhill A; Griffiths GO; Falk S; Valle JW; O'Reilly D; Siriwardena AK; Hornbuckle J; Rees M; Iveson TJ; Hickish T; Garden OJ; Cunningham D; Maughan TS; Primrose JN;
    Lancet Oncol; 2020 Mar; 21(3):398-411. PubMed ID: 32014119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyunsaturated fatty acid supplementation for drug-resistant epilepsy.
    Sarmento Vasconcelos V; Macedo CR; de Souza Pedrosa A; Pereira Gomes Morais E; Porfírio GJ; Torloni MR
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011014. PubMed ID: 27536971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
    Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
    BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unresectable Intermediate-Size (3-5 cm) Colorectal Liver Metastases: Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation (COLLISION-XL): Protocol of a Phase II/III Multicentre Randomized Controlled Trial.
    van der Lei S; Dijkstra M; Nieuwenhuizen S; Schulz HH; Vos DJW; Versteeg KS; Buffart TE; Swijnenburg RJ; de Vries JJJ; Bruynzeel AME; van den Tol MP; Scheffer HJ; Puijk RS; Haasbeek CJA; Meijerink MR;
    Cardiovasc Intervent Radiol; 2023 Aug; 46(8):1076-1085. PubMed ID: 37430016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial.
    Buisman FE; Homs MYV; Grünhagen DJ; Filipe WF; Bennink RJ; Besselink MGH; Borel Rinkes IHM; Bruijnen RCG; Cercek A; D'Angelica MI; van Delden OM; Donswijk ML; van Doorn L; Doornebosch PG; Emmering J; Erdmann JI; IJzerman NS; Grootscholten C; Hagendoorn J; Kemeny NE; Kingham TP; Klompenhouwer EG; Kok NFM; Koolen S; Kuhlmann KFD; Kuiper MC; Lam MGE; Mathijssen RHJ; Moelker A; Oomen-de Hoop E; Punt CJA; Te Riele WW; Roodhart JML; Swijnenburg RJ; Prevoo W; Tanis PJ; Vermaas M; Versleijen MWJ; Veuger FP; Weterman MJ; Verhoef C; Groot Koerkamp B
    BMC Cancer; 2019 Apr; 19(1):327. PubMed ID: 30953467
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.